) signaling pathway that operates through either primary or modulatory mechanisms. In its primary role, it generates the Ca 2ϩ that acts directly to control processes such as metabolism, secretion, fertilization, proliferation, and smooth muscle contraction. Its modulatory role occurs in excitable cells where it modulates the primary Ca 2ϩ signal generated by the entry of Ca 2ϩ through voltage-operated channels that releases Ca 2ϩ from ryanodine receptors (RYRs) on the internal stores. In carrying out this modulatory role, the InsP 3 /Ca 2ϩ signaling pathway induces subtle changes in the generation and function of the voltage-dependent primary Ca 2ϩ signal. Changes in the nature of both the primary and modulatory roles of InsP 3 /Ca 2ϩ signaling are a contributory factor responsible for the onset of a large number human diseases. 
I. INTRODUCTION
The inositol 1,4,5-trisphosphate/calcium (InsP 3 /Ca 2ϩ ) signaling pathway, which controls many different cellular processes, operates through either a primary or a modulatory mode (FIGURE 1). Its primary role is evident in nonexcitable cells where it generates the Ca 2ϩ signals to control processes as diverse as metabolism, secretion, fertilization, proliferation, and smooth muscle contraction (34, 38, 39, 249) . In excitable cells, the primary Ca 2ϩ signal depends on the entry of Ca 2ϩ through voltage-operated channels, which can be enhanced by the release of Ca 2ϩ by ryanodine receptors (RYRs) on the internal stores. This primary Ca 2ϩ pathway regulates processes such as contraction in muscle cells, memory formation in neurons, and insulin secretion from beta cells. In these cases, the InsP 3 /Ca 2ϩ signaling pathway has a modulatory role in that it can induce subtle changes in the generation and function of this primary Ca 2ϩ signal. In this review, I describe how this InsP 3 /Ca 2ϩ signaling pathway plays a role in multiple cellular processes and how subtle changes in the nature of both its primary and modulatory roles contribute to the onset of a large number human diseases such as Alzheimer's disease (AD), amyotrophic lateral sclerosis (ALS), asthma, atrial arrhythmias, autism spectrum disorder (ASD), bipolar disorder, cancer, congestive heart failure (CHF), diabetes, Duchenne muscular dystrophy (DMD), epilepsy, Huntington disease (HD), hypertension, liver cholestasis, nephrolithiasis, osteoarthritis, pancreatitis, rheumatoid arthritis, schizophrenia, Sjögren's syndrome (SS), and spinocerebellar ataxias (SCAs).
B. InsP 3 Metabolism
The Ca 2ϩ -mobilizing function of InsP 3 is terminated through its metabolism by either an InsP 3 3-kinase or an inositol polyphosphate 5-phosphatase (FIGURE 2) (80, 168) . This inositol phosphate metabolism generates the inositol that is necessary to synthesize the phosphatidylinositol (PtdIns) that is required to maintain the signaling pathway. It also functions to generate a number of new inositol phosphates that operate in the inositol polyphosphate signaling pathways. The Ins1,4,5P 3 is either phosphorylated to Ins1,3,4,5P 4 by InsP 3 3-kinase or it is dephosphorylated by type I inositol polyphosphate 5-phosphatase to release Ins1,4P 2 . The two products of these pathways are then sequentially dephosphorylated by a number of inositol phosphatases to form free inositol. A key component of this metabolic pathway is the inositol monophosphatase (IMPase) that hydrolyzes InsP 1 to free inositol that is one of the precursors used for the synthesis of PtdIns on the ER. The PtdIns is then transported to the plasma membrane where it functions as the precursor for the formation of PtdIns4,5P 2 . A loss of function mutation in the IMPA1 gene, which encodes the IMPase, results in severe intellectual disability (112). Lithium (Li ϩ ) inhibits the IMPase resulting in a decline in the supply of inositol. This reduction of inositol by Li ϩ , which is the basis of the inositol depletion hypothesis (46, 48) , may explain its action in controlling various neurodegenerative diseases such as bipolar disorder (BPD), Alzheimer's disease (AD), and HD. Li ϩ can also delay the progression of ALS (116). The inositol depletion hypothesis thus provides further evidence that these diseases may be caused by an excessive elevation of the neuronal phosphoinositide signaling pathway as described later. The fact that Li ϩ can improve non-rapid-eye-movement (NREM) sleep (122, 281) also supports the possibility that the InsP 3 /Ca 2ϩ signaling pathway is an important component of the tonic excitatory drive that regulates brain rhythms as described later (42) .
Mutations in the OCRL1 gene, which encodes inositol polyphosphate-5-phosphatase that converts inositol 1,4,5-trisphosphate to inositol 1,4-bisphosphate and inositol FIGURE 1. In response to agonists, activated receptors stimulate phospholipase C (PLC) that hydrolyzes phosphatidylinositol 4,5-bisphosphate (PtdIns4,5P 2 ) to form diacylglycerol (DAG) and inositol 1,4,5-trisphosphate (InsP 3 ). The InsP 3 diffuses into the cell where it interacts with the InsP 3 receptor to release Ca 2ϩ , which acts as a primary signal to activate processes such as fertilization, proliferation, metabolism, and secretion. In excitable cells, the primary Ca 2ϩ signal is generated by receptor-operated channels (ROCs) or voltageoperated channels (VOCS) that promote the entry of external Ca 2ϩ . This primary signal can be augmented by Ca 2ϩ stimulating ryanodine receptors (RYRs) to release Ca 2ϩ from internal stores. The InsP 3 /Ca 2ϩ signaling pathway can modulate this primary signal that functions to control processes such as neuronal excitability, beta-cell insulin secretion, and contraction of skeletal and cardiac cells.
1,3,4,5-tetrakisphosphate to inositol 1,3,4-trisphosphate, causes Oculocerebrorenal syndrome of Lowe (OCRL) that is an X-linked disorder characterized by congenital cataracts and mental retardation (221) .
C. InsP 3 R Activation by InsP 3 and Ca

2؉
The primary mode of action of InsP 3 is to bind to InsP 3 Rs to release Ca 2ϩ from the ER (106, 119, 229, 248, 249, 370, 371, 387) . The InsP 3 R consists of four subunits that form a tetrameric channel that is embedded in the ER and in the nuclear envelope (NE) (FIGURE 3) (370) . The InsP 3 Rs consist of three isoforms: InsP 3 R1, InsP 3 R2, and InsP 3 R3 that have similar primary structures, but different physiological properties. Cells exploit these different properties to create Ca 2ϩ signals with different spatial and temporal characteristics to control many different cellular functions. The structure of individual subunits consists of three main domains (370, 371) . The receptor is embedded in the ER by six transmembrane domains (TM), and there is a pore (P) loop that connects TM5 to TM6. The loops that extend into the lumen of the ER are glycosylated. An InsP 3 R-binding domain is located at the end of the long NH 2 -terminal cytoplasmic region and is connected to TM1 by the modulatory domain. The conformational change induced by the binding of InsP 3 and Ca 2ϩ is transmitted down to the transmembrane region to open the pore. Many regulators of InsP 3 Rs act on the modulatory domain to control the release of Ca 2ϩ (FIGURE 4).
The Ca 2ϩ -mobilizing second messenger InsP 3 and Ca 2ϩ are the primary regulators of the InsP 3 R (119, 229, 387) . Acti-FIGURE 2. The cell-surface receptors responsible for InsP 3 formation belong to two main classes, the G protein-coupled receptors (GPCRs) and the protein tyrosine kinase-linked receptors (PTKRs) that are coupled to different phospholipase C (PLC) isoforms. The the GPCRs use the PLC␤ isoforms, whereas the receptor tyrosine kinases (RTKs) are coupled to the PLC-␥ isoforms. During the transduction process, the precursor lipid PtdIns4,5P 2 is hydrolyzed by PLC to produce both InsP 3 and diacylglycerol (DAG). The InsP 3 released from the membrane diffuses into the cytosol where it engages the InsP 3 receptors (InsP 3 Rs) to release Ca 2ϩ from the endoplasmic reticulum. The Ca 2ϩ -mobilizing function of InsP 3 is terminated through its metabolism by either InsP 3 3-kinase or InsP 3 5-phosphatase. The resulting InsP 2 and InsP 4 enter an inositol phosphate metabolic pathway and are recycled back to free inositol. The DAG is recycled back to the precursor CDP-DAG, which then combines with inositol to reform the phosphatidylinositol (PtdIns) that is returned to the plasma membrane to be phosphorylated to the PtdIns4,5P 2 precursor to maintain the InsP 3 signaling pathway. A key component of this metabolic pathway is the inositol monophosphatase (IMPase) that hydrolyzes InsP 1 to free inositol. This IMPase is inhibited by lithium (Li ϩ ), which thus acts to reduce the supply of inositol resulting in a decline in the activity of the InsP 3 /Ca 2ϩ signaling pathway.
vation of release begins when InsP 3 binds to the InsP 3 -binding domain. Before the channel opens, InsP 3 has to bind to each of the four subunits (6) . Once InsP 3 has occupied all four monomers, it induces a conformational change, which sensitizes the Ca 2ϩ -binding site. When Ca 2ϩ binds to this site, the channel opens and Ca 2ϩ is released into the cytoplasm (FIGURE 3). The action of Ca 2ϩ is bimodal in that it stimulates release at low levels, but when Ca 2ϩ rises above 300 nM, it becomes inhibitory. This dual control of the InsP 3 R by both InsP 3 and Ca 2ϩ is central to its multiple functions in cell signaling.
D. InsP 3 -Induced Ca 2؉ Oscillations
A characteristic feature of the InsP 3 signaling pathway is that it usually acts to release Ca 2ϩ as brief transients. If signaling has to occur over a longer period, such spikes are repeated to give oscillations (33, 37, 111) . Oscillations have been described in multiple cell types such as the insect salivary gland (311) , hepatocytes (319, 403) , osteoclasts (367) , astrocytes (95), renal epithelial cells (2) , mesoepithelial cells (293) , pancreatic acinar cells (124, 296) , oocytes (72, 84) , and endothelial cells (258) . A characteristic feature of these oscillations is that their frequency depends on the level of stimulus intensity (36, 47) . Many functions such as salivary gland secretion, liver metabolism, smooth muscle contractility, and differential gene transcription, especially in developing systems, are controlled by such frequency coding. Gene expression is initiated more effectively using Ca 2ϩ spikes rather than the same average Ca 2ϩ concentration maintained at a steady level (209) . The transcription factor NFB is activated by low frequency spikes, whereas NF-AT activation requires higher frequencies (99). Changes in Ca 2ϩ oscillation frequency can also regulate the activity of the protein kinase CaM kinase II (91).
Just how these oscillations are generated is still a matter of considerable debate. In some of the earliest models, it was suggested that the oscillator was based on a periodic sensitization of the InsP 3 R brought about by recharging of the intracellular store through the entry of external Ca 2ϩ (37) . In some cells, such entry is not necessary because much of the Ca 2ϩ released during each transient is taken back into the ER. More recent studies have indicated that the oscillatory mechanism is more complicated as there are indications that the level of InsP 3 can oscillate together with the Ca 2ϩ (301) . The current concept is that oscillations may be driven by complex feedback interactions operating between InsP 3 and Ca 2ϩ (129, 144, 301, 421) . (18, 287, 361) and can also reduce the symptoms of acute pancreatitis (164) .
E. InsP 3 R Regulation
Another group of proteins that interact with the InsP 3 Rs are some of the protooncogenes and tumor suppressors such as Bcl-2, BRCA1, PTEN, and PML. In general, the protooncogenes reduce InsP 3 R activity, whereas tumor suppressors tend to enhance InsP 3 R function resulting in apoptotic cell death. For example, the breast cancer 1 (BRCA1) protein binds to the InsP 3 R to enhance Ca 2ϩ release that then induces apoptosis (149) . Conversely, Bcl-2 acts to inhibit the InsP 3 R to reduce Ca 2ϩ release (73, 318) with important implications for human diseases such as AD, BPD, cancer and HD (98, 140) . Another important regulator that has implications for neural diseases is carbonic anhydrase-8 (Car8), which is an allosteric inhibitor of InsP 3 R1 (156, 157, 425) . Alterations in this regulation of the InsP 3 /Ca 2ϩ signaling pathway by Car8 has been implicated in chronic inflammatory pain (425) . The receptor is also sensitive to reactive oxygen species (ROS) such as hydrogen peroxide (H 2 O 2 ), and this action can be mimicked by thimerosal. A number of modulators can influence activity either positively (green arrows) or negatively (red arrows). Channel activity is modulated by phosphorylation through various signaling pathways using messengers such as cAMP, cGMP, and PtdIns3,4,5P 3 (PIP 3 ). Some of these phosphorylations are reversed by protein phosphatase 1 (PP1). High levels of Ca 2ϩ inhibit the receptor. There also are a range of pharmacological agents that have been used to inhibit release of Ca 2ϩ by the InsP 3 R.
The activity of the InsP 3 Rs is regulated by a cycle of phosphorylation and dephosphorylation operated by a number of protein kinases and phosphatases (383, 418 signaling pathway plays a role in both aging and in many of the diseases linked to vitamin D deficiency (44, 45) .
The InsP 3 /Ca 2ϩ signaling pathway is also regulated by varying the cellular level of the InsP 3 Rs, which depends on the balance between the synthesis of these receptors through transcription and expression and its removal by the endoplasmic reticulum-associated degradation (ERAD) pathway (see below). A number of mechanisms, many of which act through Ca 2ϩ , regulate InsP 3 R transcription (132, 138, 256, 257) . These studies reveal that L-type voltage-gated channels, NMDARs, nicotinic acetylcholine receptors (nAChR), and D1 dopamine receptors all act by increasing intracellular levels of Ca 2ϩ responsible for triggering expression of InsP 3 Rs. Transcription of InsP 3 Rs is also regulated in a Ca 2ϩ -independent manner by factors such as tumor necrosis factor-␣ (TNF-␣) acting through the specificity protein 1 (SP-1) (289, 408) . The nuclear factor, erythroid 2-Like 2 (NRF2) transcription factor acts to reduce transcription of the type 3 InsP 3 R (InsP 3 R3) (397) . Finally, various drugs such as psychostimulants, morphine, cocaine, methamphetamine, and nicotine increase the transcription of InsP 3 R1, and this might be relevant to their addictive behavior (201, 202, 257) .
The subsequent expression of the InsP 3 R mRNAs can be regulated by microRNAs (miRs), which function as posttranscriptional regulators. In cardiomyoctes, miR-133a acts to inhibit the expression of InsP 3 R2 (100, 387). Downregulation of miR-133a accounts for an increase in the level of the InsP 3 R2s, and this is a major contributory factor for the onset of cardiac hypertrophy. The expression of InsP 3 R3 in cholangiocytes, which function in bile secretion, is suppressed by miR-506 (13). As described later, this decline in InsP 3 R3 expression is responsible for a number of cholestatic disorders such as bile duct obstruction, biliary atresia, and biliary cholangitis/cirrhosis. These transcription and expression mechanisms responsible for the synthesis of InsP 3 Rs are balanced by a pathway that removes the functional receptors through the ERAD pathway (222, 405) . This ERAD mechanism depends on the ubiquitin-proteasome pathway (UPP) that degrades the InsP 3 Rs while they are functioning in the ER. The InsP 3 Rs are polyubiquitinated and are then recognized and degraded by the proteasomes. This ubiquitination is carried out by RNF170, which is a RING domain-containing protein ligase that resides on the ER, where it recognizes and associates with activated InsP 3 Rs (222, 405 . A constitutive Ca 2ϩ release by the InsP 3 R may create a local elevation of Ca 2ϩ within the narrow gap between the ER and the mitochondria where it activates mitochondrial energy metabolism to maintain the formation of ATP that then acts to prevent autophagy by reducing the activity of AMP-activated protein kinase (AMPK). This Ca 2ϩ signaling operates within the ER/mitochondrial shuttle, which means that this highly localized Ca 2ϩ signal is hidden away from the other cytosolic Ca 2ϩ -sensitive processes.
Elevation in various pathological aggregates such as amyloid, tau, ␣-synucleins and mutant Huntington fragments, which contribute to neurodegenerative disease such as AD, Parkinson's disease, and HD, may accumulate because of a decline in autophagy. These diseases are also associated with abnormal elevations in the InsP 3 /Ca 2ϩ signaling pathway that may act to reduce autophagy. Such a mechanism may explain the observation that Li ϩ can induce autophagy in some of these diseases through inhibition of the IMPase (FIGURE 2) resulting in inositol depletion and a subsequent reduction in the InsP 3 -induced flux of Ca 2ϩ that acts to reduce autophagy (115, 262, 325, 326, 327) .
III. InsP 3 /Ca 2؉ SIGNALING AND DISEASE
The InsP 3 /Ca 2ϩ signaling pathway is a major component of the highly versatile and dynamic cellular Ca 2ϩ signaling system that regulates many different cellular processes (49, 50, 118, 249) . One of the striking features of InsP 3 /Ca 2ϩ signaling is its role in the development of multiple human diseases (TABLE 1) (40, 52, 53, 118, 249) . When considering this pathological role, it is important to consider how vitamin D deficiency may act to enhance the alterations in the InsP 3 /Ca 2ϩ signaling pathway. Vitamin D may act by maintaining the phenotypic stability of both the Ca 2ϩ and the redox signaling pathways (44, 45) . During Vitamin D deficiency, an increase in the resting state of these pathways would greatly enhance the activity of the InsP 3 /Ca 2ϩ signaling pathway. In the following sections, the role of InsP 3 / Ca 2ϩ signaling in different cell types will be described to illustrate how alterations in this signaling pathway contributes to different disease states.
IV. CELL PROLIFERATION
One of the important signals responsible for inducing cell proliferation is an increase in Ca 2ϩ (35, 300, 313) . For example, histone-induced proliferation of cholangiocytes is driven by the InsP 3 /Ca 2ϩ signaling pathway (120, 121) through a mechanism that can be suppressed by miR-506, which is known to act by reducing InsP 3 R expression (13) . One of the actions of InsP 3 is to generate a nucleoplasmic Ca 2ϩ signal that is responsible for activating proliferation (314) . In liver regeneration, InsP 3 /Ca 2ϩ signaling triggers hepatocyte proliferation to create the new liver cells to restore liver function (276) . The following examples illustrate further how the InsP 3 /Ca 2ϩ signaling pathway has a prominent role in generating the Ca 2ϩ signals that drive cell proliferation and how alterations in this signaling pathway contribute to acute lymphoblastic leukemia, asthma, cancer, infertility, and severe combined immune deficiency (SCID).
A. Fertilization
Before sperm can fertilize the oocyte, they have to become hyperactive to enable them both to pass through the mucous layer within the oviduct and to penetrate the zona pellucida to react with the oocyte plasma membrane. This hyperactivity is driven by an increase in Ca 2ϩ released by InsP 3 Rs located in the redundant nuclear envelope (RNE) that surrounds the sperm axoneme (158) . This hyperactive state is triggered by vitamin D acting in a nongenomic mechanism to activate the formation of the InsP 3 responsible for the release of Ca 2ϩ (60, 61) .
At fertilization, the sperm fuses with the oocyte and injects phospholipase C (PLC), which is unique to sperm, where it hydrolyzes PtdIns4,5P 2 to form InsP 3 that acts through the InsP 3 Rs to trigger the Ca 2ϩ oscillations that activates the egg to begin its development (272, 362, 390 Mutations in PLC are responsible for some cases of male infertility (11, 272) . Activation of B cells is driven by the B-cell antigen receptor (BCR), which assembles a hetero-oligomeric complex made up of two Ig␣ and Ig␤ signaling proteins that are associated with the antigen-binding immunoglobulin IgM receptor that consists of two heavy chains and two light chains. When antigen binds to the IgM, it activates Lyn that is a non-receptor tyrosine kinase that phosphorylates tyrosine residues located on the immunoreceptor tyrosine-based activation motifs (ITAMs) in the cytoplasmic regions of Ig␣ and Ig␤. The phosphorylated ITAMs recruit and activate various transducing components such as phospholipase C␥2 (PLC␥2). Following activation of PLC␥2, PtdIns4,5P 2 is hydrolyzed to form InsP 3 and DAG that contribute to the activation of proliferation (155, 392 (20, 155) . This gives rise to a prolonged Ca 2ϩ signal, which is encoded in the form of repetitive Ca 2ϩ oscillations (255) , that activates NFAT resulting in B-cell activation characterized by proliferation and differentiation (19, 329) . In T cells, proliferation and cytokine production depend on a sustained Ca 2ϩ signal that results from the activation of the InsP 3 /Ca 2ϩ signaling system in a manner similar to that just described for the B cells (109, 160, 275 
B. Lymphocyte Proliferation
C. Cancer
There is increasing evidence for a link between Ca 2ϩ signaling and cancer (260, 303, 313) . Alterations in the InsP 3 / Ca 2ϩ signaling system is responsible for some of the aberrant Ca 2ϩ signaling changes in cancer cells. For example, chromosome instability results in changes in phosphoinositide signaling pathways, some of which lead to elevated levels of InsP 3 , have been described in glioblastoma multiform that is one of the commonest brain tumors (396) . The proliferation and migration of human gastric adenocarcinoma cells is driven by the InsP 3 /Ca 2ϩ and DAG/PKC signaling pathways operating in parallel with each other (86).
Mutations in the PLCG1 and PLCG2 genes that encode PLC␥1 and PLC␥2, respectively, have been linked to a number of cancers (196) . The PLC␥1 mutations have been found in secondary angiosarcoma (30) and cutaneous T-cell lymphoma (CTCL) (386) . Deletions in the INPP5A gene, which encodes the InsP 3 5-phosphatase that metabolizes InsP 3 (FIGURE 2), have been found in squamous cell carcinoma (SCC) (337) and brain tumors (205) . Likewise, there is a decline in the expression of the 5-phosphatase in human leukemias (245) . Chronic lymphocytic leukemia (CLL), which is driven by alterations in B-cell Ca 2ϩ signaling (89), has been linked to mutations in PLC␥2 (404) . Genetic polymorphisms of the ITPKC gene, which encodes the InsP 3 3-kinase C protein that inactivates InsP 3 (FIGURE 2), have been linked to an increased risk of developing cervical squamous cell carcinoma (413) . Proliferation of cancerous pancreatic duct cells is driven by uridine triphosphate (UTP) that acts through the InsP 3 /Ca 2ϩ signaling pathway (76) . The high expression of InsP 3 R2 has been considered to be a novel biomarker of acute myeloid leukemia (341) . In many of these cases, there are indications that the mutations in the InsP 3 pathway result in the elevated Ca 2ϩ signals that contribute to the control proliferation.
The InsP 3 R, which releases Ca 2ϩ from the ER, has been linked to processes that contribute to cancer (3, 150, 321, 364) . The proliferation of breast cancer cells depends on InsP 3 R3 channels (263) . Dissemination of gastric cancer cells may depend on InsP 3 R3-induced elevation of Ca 2ϩ (321) . Caffeine inhibition of InsP 3 R3s was found to reduce the survival, migration, and invasion of glioblastoma cells (180) . In colon cancers, higher expression levels of InsP 3 R3s are associated with enhanced aggressiveness and poorer prognosis (343) . Locomotion of human melanoma cells is enhanced by autocrine motility factor (AMF) that acts through the InsP 3 /Ca 2ϩ signaling pathway (195) . Many of the regulatory proteins that control the activity of these InsP 3 Rs are protooncogenes and tumor suppressors such as Bcl-2, Beclin 1, BRCA1, MCL-1, PTEN, and PML (FIGURE 4) (3, 57, 140) . In B cells, PKB/Akt2 can inhibit Ca 2ϩ release by promoting the activity of Bcl-2, which is known to inhibit the InsP 3 Rs (235).
In general, the protooncogenes reduce InsP 3 R activity, whereas tumor suppressors tend to enhance InsP 3 R function resulting in apoptotic cell death. For example, breast cancer 1 (BRCA1) binds to the InsP 3 R to enhance Ca 2ϩ release that then induces apoptosis (57, 149) . Altering the activity of the InsP 3 Rs may enable prostate cancer cells to resist the androgen deprivation treatment that normally acts to kill these cancer cells (64) . Conversely, Bcl-2 acts to inhibit the InsP 3 R to reduce Ca 2ϩ release (73, 318) with important implications for human diseases such as cancer, BPD, AD, and HD (98, 140). For example, Bcl-2 interacts with the InsP 3 Rs to reduce the release of Ca 2ϩ , which prevents apoptosis and is responsible for the survival of cancer cells (140) . In a similar way, oncogenic K-Ras can promote cancer cell survival by suppressing the InsP 3 -mediated release of Ca 2ϩ that drives apoptosis (297) .
V. NEURONAL SIGNALING
The InsP 3 /Ca 2ϩ signaling pathway contributes to both brain development and many of its functions such as axonal growth (137), memory formation (166, 320) , excitability, brain rhythms (42, 151, 358) , and gene transcription (209) . The neural circuits in the brain consist of excitatory and inhibitory neurons that interact with each other as part of the mechanisms responsible for generating brain rhythms. Changes in the role of InsP 3 /Ca 2ϩ signaling in regulating these neuronal functions are responsible for many neurodegenerative diseases (40, 41, 52, 53, 118) .
A. Brain Development
Development of the brain proceeds through a number of distinct phases such as proliferation, migration, and differentiation. First, the embryonic cells, which are set aside to form the brain, begin to proliferate rapidly to form a large population of neuronal precursors. In the next step, these neuronal progenitors begin to differentiate into the specific neuronal cell types that constitute fully functional neuronal circuits. PLC␥1, which generates the InsP 3 /Ca 2ϩ signaling pathway, plays an important role in brain development (181) . This pathway induces the Ca 2ϩ oscillations that regulate both proliferation and differentiation (380, 398) . As neurons develop, axons grow out to interact with other neurons and the InsP 3 signaling systems contributes to the mechanism that steers the growth cones towards their targets (378) . During differentiation, neurons begin to express different neurotransmitters, which mark the emergence of either excitatory or inhibitory neurons. This specification seems to be determined by the generation of spontaneous Ca 2ϩ transients. All the cells become active, and those with the highest oscillation frequency act as pacemakers that then recruit neighboring cells giving rise to a Ca 2ϩ wave that creates oscillating hubs of cells.
Expression of excitatory transmitters such as acetylcholine (ACh) and glutamate occur in neurons that have low-frequency oscillations, whereas inhibitory transmitters such as glycine and ␥-aminobutyric acid (GABA) are expressed in those neurons that display more frequent Ca 2ϩ transients. Fully functional neuronal circuits depend on this emergence of the excitatory and inhibitory neurons that interact with each other to generate the rhythms that are essential for brain function (42) . The normal function of the brain is critically dependent on the activity of these neurons being balanced. Such excitation-inhibition balance (E-I balance) is critical to maintain normal brain rhythms, and alterations in this balance have been implicated in a number of neural diseases as described below.
B. Brain Rhythms
Having contributed to the development of the brain, the InsP 3 /Ca 2ϩ signaling pathway continues to control adult brain functions such as the regulation of brain rhythms and synaptic plasticity.
During the sleep/wake cycle, the brain has different neural rhythms (FIGURE 5). During the awake state there are a number of brain rhythms such as the fast gamma (20-80 Hz), alpha (8) (9) (10) (11) (12) , and theta (6 -10 Hz) oscillations. During sleep, the rhythm frequency declines resulting in the delta (1-4 Hz) and slow oscillations (Ͻ1 Hz). The ascending arousal system is responsible for regulating the activity of these different oscillatory modes. This arousal system consists of a variety of neurons that project their axons throughout the brain where they release transmitters such as orexin, ACh, norepinephrine (NE), 5-hydroxytryptamine (5-HT), histamine, and dopamine (DA). These transmitters are released globally and are thus able to act simultaneously on both the excitatory and inhibitory neurons that form the functional neural circuits (42, 87, 283) . These transmitters act through a number of pathways to induce the depolarization that constitutes the tonic excitatory drive that controls the different brain rhythms. Different signaling mechanisms are responsible for generating this tonic excitatory drive (FIGURE 5). PtdIns4,5P 2 hydrolysis causes depolarization by closing the K V 7.2/K V 7.3 K ϩ channels that depolarizes the membrane by switching off the M current. The InsP 3 that is released by the hydrolysis of PtdIns4,5P 2 also contributes to depolarization by releasing Ca 2ϩ that activates the Ca 2ϩ -activated nonselective cation (CAN) channel. The Cav1.2 L-type Ca 2ϩ channel also contributes to the membrane depolarization in that it generates a Ca 2ϩ signal that also activates the CAN channel. Neuronal excitability is also regulated by DA and NE that operate through the cAMP signaling pathway. Inactivation of the D2 receptors in the dorsolateral prefrontal cortex (DLPFC) is prevented by neuronal calcium sensor 1 (NCS-1). It is of interest, therefore, to find that the levels of NCS-1, which activates the InsP 3 R, are markedly elevated in BPD (332) .
Most of the neural circuits in the brain depend on interactions between excitatory and inhibitory neurons that are responsible for the oscillatory activity that characterizes these brain rhythms. In order for the system to operate normally, the response of each neuronal cell type to the tonic excitatory drive must be finely balanced. To achieve this balance, the synaptic inputs operating between the excitatory and inhibitory neurons must be equal. There are indications that alterations in this excitation-inhibition (E-I) balance may occur in various psychiatric diseases such as autism spectrum disorder (ASD), epilepsy, and schizophrenia (102, 234). There may also be a link between alterations in the tonic excitatory drive and BPD in that excessive excitation may be responsible for the manic phase, whereas depression may result from excessive inhibition as described below.
A decline in the activity of these arousal signaling pathways is responsible for sleep. The signaling pathways are not switched off completely as a low level of stimulation is responsible for maintaining the slow wave sleep rhythm (31) . The InsP 3 /Ca 2ϩ signaling pathway may contribute to the operation of the pacemaker mechanism that drives the slow waves that characterize NREM sleep. Such a possibility is consistent with the observation that Li ϩ , which acts by reducing the activity of the InsP 3 /Ca 2ϩ signaling pathway (48) , is capable of converting rapid eye movement (REM) sleep to NREM sleep (122, 281). Conversely, the accumulation of amyloid-␤, which acts to increase the InsP 3 /Ca 2ϩ signaling pathway, disrupts NREM sleep leading to a decline in memory formation (233) .
C. Memory
The first indication that InsP 3 may play a role in memory emerged from studies of long-term depression (LTD) in cerebellar Purkinje cells. These Purkinje cells, which play an important role in motor learning and coordination, depend on the process of LTD at the synapses where parallel fibers innervate the Purkinje cells. The parallel fibers release glutamate that acts on metabotropic glutamate receptors (mGluR) that are coupled to PLC␤ to generate InsP 3 that then acts on InsP 3 Rs on extensions of the ER that project into the spines to control LTD (166) . These InsP 3 Rs function as coincident detectors in that they only open when both InsP 3 and Ca 2ϩ signals are present. The parallel fibers produce the InsP 3 , whereas the climbing fibers induce the membrane depolarization that opens the L-type Ca 2ϩ channels to generate the Ca 2ϩ . For the channel to open, both messengers need to be present, and this InsP 3 R-mediated coincident detection then generates the Ca 2ϩ signal necessary for the synaptic plasticity that underlies motor learning. In addition to its role in activating LTD in Purkinje neurons, InsP 3 also plays a central role in activating LTD in other neurons (22, 65, 411) .
In keeping with the role of the InsP 3 /Ca 2ϩ signaling pathway in many neural functions, there is increasing evidence that alterations in this pathway are responsible for many neural diseases such as AD, ALS, ASD, BPD, epilepsy, HD, and spinocerebellar ataxias (SCAs).
D. Alzheimer's Disease (AD)
AD is driven by an increase in the amyloidogenic pathway, which results in the release of soluble ␤-amyloid (A␤) by the neurons. These A␤ monomers form A␤ oligomers that feed FIGURE 5. The ascending arousal system, which releases transmitters throughout the brain, activates a variety of signaling pathways to generate the tonic excitatory drive responsible for regulating the brain rhythms during the sleep/wake cycle. Orexin, acetylcholine (ACh), and 5-hydroxytryptamine (5-HT) stimulate the hydrolysis of PIP 2 resulting in closure of the K ϩ channels that drives the M-current. The InsP 3 releases Ca 2ϩ that activates the Ca 2ϩ -activated nonselective cation (CAN) channels. The norepinephrine (NE) and dopamine (DA) generate cAMP that opens Na ϩ channels. These three main pathways depolarize the membrane to produce the alterations in the tonic excitatory drive that regulates the brain rhythms.
back to activate the neurons to bring about an increase in cytosolic Ca 2ϩ , which is the basis of the calcium hypothesis of AD. This elevation in neuronal Ca 2ϩ signaling induces a decline in memory and later neuronal cell death (41, 42, 139, 360) . A significant feature of this alteration in neuronal Ca 2ϩ signaling in AD is the reciprocal relationship between the amyloidogenic and Ca 2ϩ signaling pathways. The increase in Ca 2ϩ induced by the A␤ oligomers can feed back to stimulate the formation of A␤ by stimulating the hydrolysis of APP (139, 169, 298, 308) (FIGURE 6 ). This ability of Ca 2ϩ to stimulate the formation of A␤ may explain why hypoxia can result in AD pathogenesis. Hypoxia results in an increase in the activation of the Ca 2ϩ sensing receptor (CaSR), which is known to increase InsP 3 formation that may then lead on to the elevation of Ca 2ϩ (21) . One of the actions of the A␤ oligomers that are responsible for AD is to stimulate the formation of InsP 3 that then acts on the InsP 3 Rs to release Ca 2ϩ from the ER (94, 108, 171, 360, 381). There are indications that the A␤ oligomers can induce this release of internal Ca 2ϩ either by acting on cell surface receptors such as the metabotropic glutamate receptor 5 (mGluR5) that acts to increase InsP 3 (381) or by influencing the formation of InsP 3 through an intracellular action (94). In addition, the activation of the InsP 3 Rs may depend on the increase in oxidative stress that occurs in AD (176) . The effect of A␤ disruption of the internal stores of Ca 2ϩ can be rather subtle and are context dependent (203) . The contribution of excessive activation of the InsP 3 R in the etiology of AD has been emphasized in studies on transgenic mouse models where reducing the number of InsP 3 -sensitive channels greatly improved memory performance (344) .
The presenilins, which are part of the ␥-secretase intramembrane protease complex that cleaves the amyloid precursor protein (APP) to form the soluble A␤, have also been found to influence Ca 2ϩ homeostasis. Mutations in the presenilins (PS1 and PS2) result in the dysregulation of Ca 2ϩ signaling that is responsible for familial AD (FAD) (70) . Perhaps the most important action of the PS mutant protein is to increase the gating of the InsP 3 R Ca 2ϩ release channel (118, 208, 230, 359) . The resulting enhanced release of Ca 2ϩ may contribute to the elevated level of resting Ca 2ϩ that rises from 100 to 300 nM (199, 219, 240) . It is postulated that this elevation in the resting level of Ca 2ϩ will activate LTD to erase memories soon after they are formed, thus accounting for the memory loss that characterizes AD (41, 42) . As the disease progresses, the InsP 3 -induced dysregulation of Ca 2ϩ will begin to drive neuronal cell death resulting in dementia. A very similar sequence of events occurs in the astrocytes, which surround the neurons, in that the A␤ oligomers activate the InsP 3 /Ca 2ϩ signaling pathway resulting in apoptosis (280) .
The symptoms of AD in transgenic mice can be reduced by Bcl-2 (317), and this can be explained by its ability to inhibit InsP 3 receptors to reduce the release of Ca 2ϩ (FIGURE 6) (318) . Caffeine is another drug that may act to reduce the risk of dementia (18, 68, 104, 287, 361) . This proposed role of caffeine in reducing the risk of AD may be explained by its ability to inhibit Ca 2ϩ release from the InsP 3 Rs (54, 164, 322). There is increasing evidence that Li ϩ might be another potential drug to control AD (97, 185, 186, 273, 274, 391). As described below, Li ϩ acts to control BPD by reducing the activity of the InsP 3 /Ca 2ϩ signaling pathway, and such an action could explain how it might act to protect against AD (FIGURE 6) (97, 261, 391) . Patients with BPD that have been treated with Li ϩ for a long period have a much lower incidence of AD (185, 186, 273) . Treatment with Li ϩ is able to stabilize memory impairment in AD patients (273) . There also are indications that Li ϩ may be able to prevent the onset of AD. It has been shown that Li ϩ was able to prevent individuals displaying mild cognitive impairment from progressing to AD (114, 115). Such a possibility is consistent with the observation that Li ϩ , which acts by reducing the activity of the InsP 3 /Ca 2ϩ signaling pathway (48) , is capable of reducing REM sleep to increase NREM sleep (122, 281).
There is increasing evidence to show that the NREM sleep responsible for memory consolidation is disrupted by the accumulation of A␤ (175, 223, 224, 233, 316) . This decline in NREM sleep is consistent with the evidence discussed earlier that A␤ can act to increase the InsP 3 /Ca 2ϩ signaling pathway that would enhance the tonic excitatory drive thus preventing the onset of the slow waves that characterize NREM sleep (FIGURE 5). This A␤-dependent disruption of NREM sleep may also increase the progression of AD, because the rate of A␤ formation is lowest during this phase of sleep. The levels of A␤ are highest during wakefulness and decline during sleep (175, 179, 223) . Inhibition of orexin, which is one of the transmitters that drives the sleep-wake cycle (FIGURE 5), results in a decline in A␤ formation (179) . Such an action can be explained by the fact that orexin acts to stimulate the InsP 3 /Ca 2ϩ signaling pathway and its inhibition would reduce the tonic excitatory drive thus restoring NREM sleep during which there is a marked reduction in A␤ formation. All this information is consistent with the notion that A␤ accumulation acts to increase the activity of the InsP 3 /Ca 2ϩ signaling pathway that not only accounts for memory loss but it also disrupts NREM sleep to enhance A␤ formation thus contributing to the progression of AD.
E. Amyotrophic Lateral Sclerosis
The neurodegenerative disease ALS, which is also known as Lou Gehrig's disease, is caused by degeneration of the motor neurons in the brain stem, spinal cord, and motor cortex. Approximately 10% of ALS cases are caused by familial mutations, whereas the majority are sporadic. Most information is available for the mutations in the oxidant scavenger superoxide dismutase 1 (SOD1). ALS is also caused by mutations in the TAR-DNA binding protein 43 (TDP-43) TARDBP gene and in the FUS gene, which encodes the fused in sarcoma (FUS) RNA-binding protein, which in some cases can progress to frontotemporal dementia (FTD).
In the case of sporadic ALS, there have been a number of suggestions about what drives the degeneration of motor neurons. These include glutamate excitotoxicity, hyperexcitability, oxidative damage, mitochondrial dysfunction, and Ca 2ϩ dysregulation. All of these events are linked together with regard to their role in altering Ca 2ϩ homeostasis (167, 204, 366) . For example, the increase in oxidation arising from mutations in SOD1 will enhance Ca 2ϩ signaling by increasing the sensitivity of both the InsP 3 Rs and the RYRs (167, 366) . Such dysregulation of Ca 2ϩ is enhanced by the fact that motor neurons have low levels of Ca 2ϩ buffering proteins (167, 366) , which will place considerably more stress on the mitochondria and thus account for mitochondrial dysfunction. Excessive elevation in mitochondrial Ca 2ϩ levels activates the mitochondrial permeability transition pore (mPTP) that results in apoptosis and the death of motor neurons.
One reason for this Ca 2ϩ dysregulation may be the glutamate excitotoxicity and hyperexcitability of the motor neurons, which is a characteristic feature of ALS (190) . This enhanced excitability may arise through an increase in extracellular glutamate that can alter intracellular Ca 2ϩ by enhancing both ionotropic (NMDAR and AMPAR) and metabotropic glutamate receptors (mGluR1 and mGluR5) (136) . In a mouse model of ALS, reducing the expression of mGluR1 was found to improve both disease progression and survival (250) . Since the mGluR1 receptors act by stimulating phosphoinositide hydrolysis, this observation suggests that the InsP 3 /Ca 2ϩ signaling pathway may contribute to the dysregulation of Ca 2ϩ that is responsible for ALS (366) . Such a role for the InsP 3 /Ca 2ϩ signaling pathway can explain why Li ϩ can delay the progression of ALS (116). As described earlier, Li ϩ inhibits the IMPase resulting in a reduction in the activity of this InsP 3 /Ca 2ϩ signaling system (48) .
Such a role for InsP 3 /Ca 2ϩ signaling in ALS is supported by a number of other observations. Antibodies isolated from patients with ALS were found to stimulate the activity of the InsP 3 /Ca 2ϩ signaling pathway in motor neurons (285) . The life span of transgenic mice containing the mutant SOD1 gene was reduced when the expression of the InsP 3 R was increased (353) . Expression of PLC␦1, which is responsible for generating InsP 3 , was found to be increased in the neurons of the transgenic ALS mouse. Furthermore, the survival of these ALS mice was prolonged following genetic ablation of PLC␦1 (354) . An increase in activity of the InsP 3 /Ca 2ϩ signaling pathway may contribute to ALS through its ability to alter the activity of 43 kDa TAR DNAbinding domain protein (TDP-43). Mutations in TDP-43 result in the aggregation of TDP-43 in the cytoplasm, and this contributes to the deterioration of the motor neurons in ALS. This pathological activity of TDP-43 is regulated by Ca 2ϩ release from the InsP 3 R1 channels (189) . Increasing the activity of InsP 3 /Ca 2ϩ signaling thus promotes the nucleocytoplasmic shuttling of TDP-43 resulting in its accumulation in the cytoplasm where it exerts its deleterious effects on motor neuron survival.
F. Autism Spectrum Disorders
A number of diseases such as autism, Asperger's syndrome, perverse developmental disorder not otherwise specified (PDD-NOS), and Rett syndrome fall under the umbrella of ASD. ASD is a neurodevelopmental disorder that results in a lack of social communication especially with regard to appreciating how other people feel. ASD appears during childhood and continues into adulthood. Trying to understand this syndrome is difficult because there is considerable heterogeneity at both the genetic and phenotypic levels (135, 299) .
The neurodevelopmental aspect of ASD is based on the fact that it appears to be linked to alterations in the mechanism responsible for development of the nervous system. As described earlier, spontaneous Ca 2ϩ signals begin to appear in certain neuronal generator cells that become pacemaker cells that spread excitation to neighboring cells to form large signaling hubs. This Ca 2ϩ signaling contributes to the neuronal differentiation responsible for synapse formation that creates the neuronal circuits in the developing brain.
Recent evidence suggests that ASD results from defects in the Ca 2ϩ signaling processes responsible for setting up the structure and function of neural assemblies and particularly the synapses (101, 135, 198) . The Ca 2ϩ signaling system is one of the important pathways responsible for orchestrating the complex process of brain development. A key element in this regulation is the expression of the Ca 2ϩ buffer parvalbumin (PV). When the level of PV declines, there is an alteration in the function of inhibitory neurons that will alter the excitation-inhibition (E-I) balance, and this leads to the onset of ASD (113, 269). Such a mechanism may explain why vitamin D deficiency, which normally functions to maintain the expression of PV and many other components of the Ca 2ϩ signaling toolkit (44, 45) , has been linked to ASD (107, 172). The InsP 3 /Ca 2ϩ signaling pathway plays a key role in regulating both proliferation and differentiation during early development (380, 398) . It is not surprising, therefore, to find that alterations in the activity of this InsP 3 /Ca 2ϩ signaling system may contribute to the onset of autism (135, 333) . Studies on the fibroblast taken from autistic patients reveal that there is a marked decline in the InsP 3 -induced release of Ca 2ϩ (333) . Such an observation is consistent with a study of the genetic variants of the oxytocin receptor that have been identified in patients with autism, which also displayed a decline in the InsP 3 / Ca 2ϩ signaling pathway (225).
G. Bipolar Disorder
A characteristic feature of BPD is the extreme swings between mania and depression. It is still not clear what is responsible for these alternating manic-depressive episodes. These changes in behavior seem to depend on alterations of neuronal signaling, which are a feature of the two hypotheses that attempt to explain BPD. In the neurogenesis hypothesis, it is suggested that there is an alteration in the hippocampal circuitry that arises from a change in neurogenesis induced by stress. The inositol depletion hypothesis is based on the observation that Li ϩ acts by inhibiting the inositol monophosphatase (IMPase) that hydrolyzes inositol monophosphates (Ins4P, Ins1P, and Ins3P) to form free inositol (46, 48) . As a result of this inhibitory action, Li ϩ reduces the supply of free inositol necessary to resynthesize the inositol lipids that are required to maintain the InsP 3 / Ca 2ϩ signaling system, thus resulting in a decline in the activity of this signaling pathway (FIGURE 2). Li ϩ acts through an uncompetitive mechanism that enables this drug to have minimal effects when the InsP 3 /Ca 2ϩ signaling pathway is functioning normally, but its efficacy increases as the signaling pathway becomes increasingly abnormal. In effect, Li ϩ can be considered to be a homeostatic drug, because it has no effect when the system is operating normally, but its therapeutic action becomes increasingly effective to match the degree of hyperactivity of the InsP 3 /Ca 2ϩ signaling pathway. In effect, the therapeutic action of Li ϩ is tailored to the severity of the disease state. These actions of Li ϩ to reduce the InsP 3 /Ca 2ϩ signaling pathway led to the idea that BPD may arise as a result of an overactive phosphoinositide signaling pathway (46, 48) . Such a conclusion is supported by the observation that the levels of G␣ q/11 and PLC␤1, which are key components of the phosphoinositide signaling pathway, are elevated in the occipital cortex from patients with BPD (236) . In addition, it has been shown that stimulating InsP 3 Rs and RYRs creates a depression-like response in mice, whereas inhibition of these channels has an antidepressant-like effect (125).
Ebselen, which is a Li ϩ mimetic that also acts by inhibiting the IMPase, may be a safer drug for controlling BPD (347, 348) . Li 2ϩ may also act by inhibiting the stimulatory action of the neuronal calcium sensor 1 (NCS-1) on the InsP 3 R1 A characteristic feature of BPD is the process of switching from depression to the opposite state of mania, and vice versa (323, 373, 417) . Alterations in the activity of various neurotransmitters may play a role in this switching process and is the basis of the catecholaminergic-cholinergic balance hypothesis (385) . For example, the switch from depression to mania may be regulated by elevations in the levels of norepinephrine and dopamine (417) . Conversely, the switch from mania to depression may depend on elevations in acetylcholine. Understanding the nature of this switching process would greatly enhance our understanding of BPD, but as yet the mechanism is still unclear.
It is possible that the symptoms of BPD, and particularly the switching between depression and mania, may arise from defects in the E-I balance that controls the neuronal activity responsible for driving brain rhythms as described earlier (FIGURE 5) (43, 369) . Similarly, it has been proposed that major depressive disorder (MDD) may be caused by an alteration in excitatory transmission (374) . Such a mechanism is particularly interesting in that Li ϩ , which acts to restore the neuronal imbalance, acts to enhance synapse formation by altering the level of phosphoinositides (187) . It is also significant that the transmitters that have been implicated in the switching process also regulate the tonic excitatory drive. An alteration in the activity of these transmitters is thus consistent with the idea that an E-I imbalance may be the cause of BPD, because many of these transmitters activate the tonic excitatory drive using a variety of signaling mechanisms (FIGURE 5) (42) . For example, some of these transmitters (ACh, NE, and orexin) act to induce depolarization by stimulating the hydrolysis of PtdIns4,5P 2 to decrease the M current while the InsP 3 /Ca 2ϩ pathway promotes the Ca 2ϩ -activated nonselective cation current (I CAN ) (FIGURE 5). The possibility that hyperactivity of the InsP 3 /Ca 2ϩ pathway contributes to BPD is supported by studies showing that this disease is associated with Bcl-2 gene single nucleotide polymorphisms (SNPs), which reduce Bcl-2 expression that could result in an increase in Ca 2ϩ levels that are normally suppressed by Bcl-2 (98, 226).
Another reason for considering a possible role for changes in the tonic excitatory drive in BPD is the finding that two of the genes that have consistently been linked to BPD play a role in regulating neuronal activity. A number of genes such as CACNA1C that encodes the ␣-1C subunit of the Cav1.2 L-type Ca 2ϩ have been identified in a genome-wide association studies (12, 152, 346, 349, 373) CAN channel (FIGURE 5) . The other gene is ANK3 that encodes ankyrin-G, which plays a role in positioning the K V 7.2/K V 7.3 channels to the correct location in the neuronal membrane. K v 7.2 and K v 7.3 are delayed rectifier channels that contribute to the regulation of neuronal excitability by controlling the M current.
In summary, a characteristic feature of BPD is the switching between depression and mania that may result from changes in the E-I balance that will cause mania if the excitatory neurons are hyperactive or depression if the inhibitory neurons are hyperactive (43) . Such hyperactivity, which is reduced by Li ϩ , has been confirmed in neurons taken from bipolar patients (246) . One of the causes of this imbalance is likely to be an increase in the activity of the InsP 3 /Ca 2ϩ signaling pathway. In the case of a mouse model of depression, inhibition of the InsP 3 /Ca 2ϩ signaling pathway was found to exert an antidepressant effect (125). Correcting this signaling abnormality may explain the therapeutic action of Li ϩ , which acts by reducing the activity of the InsP 3 /Ca 2ϩ signaling pathway.
H. Epilepsy
Spontaneous recurrent epileptiform discharges (SREDs) are a characteristic feature of epilepsy. Such seizure activity, which is usually induced by brain injuries such as trauma, stroke, or infections, seem to arise through an alteration in the E-I balance described earlier (355) . The activity of the inhibitory neurons appears to decline to account for the increased activity of the excitatory neurons. A number of intracellular signaling pathways such as an increases in Ca 2ϩ (92, 93, 242, 286) and nitric oxide (NO) (197) or a decrease in the PtdIns3,4,5P 3 levels (71) have been implicated in this alteration in the E-I balance. The Ca 2ϩ hypothesis (92) that proposes there is an alteration in Ca 2ϩ homeostasis appears to be particularly important because it can account for a number of features of epilepsy such as the decline in cognition (161, 402) and its relationship to AD (63, 75) .
The alteration in Ca 2ϩ homeostasis that occurs in epilepsy is caused by various brain injuries that result in a large release of glutamate that then stimulates the NMDARs to bring about a large Ca 2ϩ influx that alters the Ca 2ϩ signaling system. In particular, there is a decline in the expression of the SERCA pump on the ER and an increase in the InsP 3 /Ca 2ϩ signaling pathway (93, 286). A role for InsP 3 / Ca 2ϩ signaling has also been implicated in the onset of seizures induced by the organophosphorus (OP) compound soman, which is a chemical warfare agent. Soman was found to induce an increase in InsP 3 formation (58) that appears to be driven by an increase in the activity of the metabotropic glutamate receptors (264) .
The mechanism driving the increase in the InsP 3 /Ca 2ϩ signaling system is unclear, but it may be caused by an increase in the brain-derived neurotrophic factor (BDNF) that operates through the TrkB receptor to induce epilepsy (217) . TrkB activates PLC␥ to increase InsP 3 that acts to maintain the elevation of Ca 2ϩ . Epilepsy can be prevented by using a specific peptide to uncouple the interaction between TrkB and the PLC␥ (141) . A genome-wide transcriptomic analysis has revealed that the InsP 3 signaling pathway is genetically associated with epilepsy (252) . The significance of enhanced InsP 3 action in epilepsy is highlighted by the observation that the anti-epileptic drug levetiracetum acts to inhibit the release of Ca 2ϩ by the InsP 3 Rs (265). Depletion of Ca 2ϩ within the ER resulting from the decline in SERCA and the increased levels of InsP 3 results in an increase of store-operated Ca 2ϩ due to the activation of the STIM1/ Orai1 entry pathway (356) . The decline in SERCA resembles that found in the heart during congestive heart failure (CHF). The net result of the enhanced release of Ca 2ϩ from the ER and entry across the plasmalemma is to bring about a persistent increase in the resting level of Ca 2ϩ and the enhanced network activity that gives rise to epilepsy (356) .
The elevation in Ca 2ϩ that is triggered during a seizure persists after the seizure and can account for many of the features of epilepsy. This Ca 2ϩ elevation will increase the tonic excitatory drive, which is responsible for controlling brain rhythms (FIGURE 5), and will thus enhance neuronal excitability and could set the stage for subsequent seizures. The decline in cognition could also be explained by the elevated Ca 2ϩ that would stimulate LTD to erase memories. It has been proposed that a similar persistent elevation in Ca 2ϩ may also explain memory erasure in AD as described above (41, 42) , and it could also account for the fact that seizures are a common feature of AD (63, 75) . It seems that in both AD and epilepsy, the persistent elevation in the resting levels of Ca 2ϩ can account for both memory loss and epileptogenesis.
I. Huntington's Disease
In HD, there is a progressive decline in intellect that culminates in death after 10 -15 yr. This neurological disease has been linked to a polyglutamine expansion in the NH 2 terminus of the Huntington protein (Htt exp ) that results in an alteration in Ca 2ϩ signaling that is responsible for the death of the GABAergic medium spiny neurons located in the striatum (85). The modified Htt exp binds strongly to the COOH-terminal region of the InsP 3 R1 resulting in an increase in its sensitivity to InsP 3 , thus giving rise to larger Ca 2ϩ signals that disrupt neuronal function and induce neuronal cell death (51, 53, 106, 118, 368) . In a mouse model of HD, activation of the InsP 3 R1 causes depletion of ER Ca 2ϩ that results in store-operated Ca 2ϩ entry that contributes to the striatal synaptic loss (407) . Mutant Htt accumulation and aggregation was reduced when the levels of the InsP 3 R1 was reduced using shRNA (29) , thus confirming that the InsP 3 /Ca 2ϩ signaling pathway plays a role in HD. The significance of this pathway is also consistent with recent observations suggesting that Li ϩ , which acts to reduce the activity of InsP 3 /Ca 2ϩ signaling, may be a significant drug for treating HD (327, 331).
J. Schizophrenia
Schizophrenia occurs in ϳ1% of the human population and is a severe psychiatric condition that is characterized by hallucinations, paranoia, poor attention, decline in social interactions, and lack of motivation. There also is a decline in cognition. An alteration in brain rhythms may be responsible for the changes in these higher-order brain functions that are a feature of schizophrenia (43) . Many of the genetic susceptibility elements code for components of Ca 2ϩ signaling, thus supporting the experimental evidence indicating that changes in Ca 2ϩ signaling is a feature of schizophrenia. There is increasing support for the NMDA receptor (NMDAR) hypofunction hypothesis (350, 375) . A decline in the Ca 2ϩ signaling pathway resulting from a decrease in the activity of NMDARs alters the phenotype stability of the GABAergic inhibitory neurons. A decline in the release of the neurotransmitter GABA distorts the brain rhythms leading to an alteration in the information processing that occurs during sensory stimulation, attention selection, and working memory.
The GABAergic inhibitory neurons also express GPCRs such as the mGluR1, mGluR5, and M1 receptors that activate the InsP 3 /Ca 2ϩ signaling pathway that acts to augment the Ca 2ϩ signal that maintains phenotypic stability. There also is evidence of a decline in the activity of serotonergic neurons located in the prefrontal cortex of patients with schizophrenia (178, 239) . Many of these neurons express the 5-HT 2A that act to increase InsP 3 /Ca 2ϩ signaling (88). Alteration in this phosphoinositide signaling pathway plays a role in schizophrenia pathogenesis. Considerable interest is now focused on the metabotropic glutamate receptor 5 (mGluR5), which is closely associated with the NMDAR through scaffolding proteins such as Homer, SHANK, guanylate-kinase-associated protein, and PSD95. Alterations in mGluR5 may contribute to schizophrenia (237) , and mutations in SHANK have been linked to various neuropsychiatric diseases including schizophrenia (131, 142) . Furthermore, a deficit in ACh signaling mediated through muscarinic receptors has also been implicated in schizophrenia (328) . A decrease in the expression of the regulators of G protein signaling 4 (RGS4), which modulates the activity of the PLC␤1 that mediates the activity of these GPCRs, is a consistent feature of schizophrenia (251) . In schizophrenia patients, there are deletions of PLC␤1 in the orbital-frontal cortex (220) . Abnormal expression patterns of PLC␤1 have been observed in patients with schizophrenia (194) . Schizophrenic symptoms have also been observed in PLC␤1 knockout mice (243) .
In addition to these alterations in the transducing mechanisms responsible for generating the InsP 3 /Ca 2ϩ signaling pathway, there also is evidence for changes in the function of the InsP 3 R1s. For example, one of the actions of the susceptibility gene Disrupted-in-schizophrenia-1 (DISC1) is to alter the activity of the InsP 3 R1s (290). DISC1 interferes with the transport of the mRNA of the ITPR1 gene that encodes the InsP 3 R1s. It attaches the ITPR1 mRNA to the kinesin-1 molecular motor that then propels it down the microtubules to distribute it throughout the dendritic tree. Once in position, the ITPR1 mRNA begins to express the InsP 3 R1 channels (379) , which are key components of neuronal Ca 2ϩ signaling mechanisms.
K. Spinocerebellar Ataxias
SCA is characterized by poor coordination of movement that can affect the legs, hands, and speech. There are many different types of SCA, and some of the causes have been linked to a dysregulation of the cerebellar InsP 3 /Ca 2ϩ signaling network that alters its role in the coordination of movement (53, 66, 106, 118, 335) . Many of the ataxias have been linked to mutations in the ITPR1 gene, which encodes the InsP 3 R1 that releases Ca 2ϩ from the ER located within the spines of the Purkinje cells (365) . For example, ITPR1 is one of the genes known to be associated with SCA15 (384) . Missense mutations in the ITPR1 have also been identified in spinocerebellar ataxia type 29 (SCA29) (163) . Mutations in the ITPR1 have also been identified in children with sporadic ataxic cerebral palsy (334) . Degeneration of Purkinje cells and the onset of ataxia have been described in mice following deletion of Inpp5a, which encodes the InsP 3 5-phosphatase that is one of the major pathways for inactivating InsP 3 (FIGURE 2) (414) . The spinocerebellar ataxia type 6 (SCA6) form of this disease is caused by a mutation in the ␣ 1A subunit of the Ca V 2.1 P/Q channel that provides the Ca 2ϩ signal that acts together with InsP 3 to open the InsP 3 Rs (67). The SCA2 form is caused by mutations in ataxin-2 (Atx2), which associates with the COOH-terminal region of the Purkinje cell InsP 3 R1 resulting in an increase in its sensitivity (215) . In Russian and Japanese families with SCA, the ITPR1 gene that encodes the InsP 3 R1 was found to have a central role in SCA pathogenesis (146, 338) .
Autosomal dominant cerebellar ataxia (ADCA), which is a type of SCA, has been linked to mutations in RNF170 that is an ER membrane ubiquitin ligase. RNF170 functions to ubiquitinate activated InsP 3 Rs. The mutation of RNF170 interferes with this ubiquitination process and results in a decline in Ca 2ϩ signaling via the InsP 3 Rs and is likely to be the cause of ADCA (405) . The dysregulation of the InsP 3 / Ca 2ϩ signaling pathway results in abnormal elevation of Ca 2ϩ that alters motor coordination and progresses to a gradual degeneration of the Purkinje neurons, which is a characteristic feature of SCA. This central role of the InsP 3 R in SCA is supported by the fact that the symptoms of SCA in mice can be alleviated by suppression of this signaling pathway in Purkinje cells (183) .
VI. MUSCLE CELLS
The InsP 3 /Ca 2ϩ signaling pathway plays a role in regulating skeletal, cardiac, and smooth muscle cell functions. In skeletal and cardiac cells, InsP 3 has a modulatory role. Alterations in this modulatory role in skeletal muscle leads to Duchenne muscular dystrophy (DMD), whereas in cardiac cells it causes congestive heart failure and atrial arrhythmias (FIGURE 1). In the case of certain smooth muscle cells, it provides the primary Ca 2ϩ signal and alterations in this signal contribute to asthma and hypertension.
A. Skeletal Muscle
The InsP 3 /Ca 2ϩ signaling pathway contributes to the regulation of skeletal muscle throughout its life history. During myoblast development, it generates the Ca 2ϩ oscillations that are essential to induce the expression of the musclespecific transcription factors such as myogenin and myocyte enhancer factor 2 (MEF2) (16) . As the myoblast develops into skeletal muscle cells, they express the RYR1 that drives muscle contraction. Although the InsP 3 /Ca 2ϩ pathway does not play a direct role in excitation-contraction (E-C), it has an important modulatory role in various muscle functions.
During the process of E-C coupling, the sarcolemma action potential is converted into an increase in Ca 2ϩ that stimulates contraction. The muscle action potential, which invades the entire sarcolemma including the t-tubules where it functions to activate the Ca V 1.1 voltage-operated Ca 2ϩ channel that interacts directly with the RYR1 to release Ca 2ϩ from the SR. Once it is released, the Ca 2ϩ diffuses to the sarcomeres where it binds to the troponin C (TnC) that induces contraction by facilitating an interaction between actin and myosin.
In addition to this primary Ca 2ϩ signaling pathway, skeletal muscle retains the InsP 3 /Ca 2ϩ signaling pathway that drove development to regulate processes both in the nucleus and in the cytoplasm (83). There appear to be two mechanisms responsible for activating the PLC that generates InsP 3 : it is activated by insulin (82) and by membrane depolarization (213, 382) . The insulin-dependent activation of the InsP 3 / Ca 2ϩ pathway regulates metabolism by activating the insertion of the glucose transporter 4 (GLUT4) into the sarcolemma. The glucose that enters the cell through GLUT4 is phosphorylated by hexokinase to form glucose 6-phosphate (G6P) that is synthesized into glycogen by the glycogen synthase (82). The depolarization-induced activation of InsP 3 /Ca 2ϩ also operates to control gene transcription (382) .
B. Duchenne Muscular Dystrophy (DMD)
The InsP 3 /Ca 2ϩ signaling pathway has been implicated in DMD, which is a progressive muscle-wasting disease. This disease results from mutations in the gene that encodes dystrophin, which has been shown to result in an increase in Ca 2ϩ signaling that drives Ca 2ϩ -sensitive proteases responsible for muscle degeneration. One of the consequences of the mutations in dystrophin, which is located on the inner surface of the sarcolemma, is to enhance the activity of the InsP 3 /Ca 2ϩ signaling pathway (23, 212) . In fetal muscle, the delayed myogenesis during dystrophy is caused by the InsP 3 -dependent release of Ca 2ϩ (105). The dystrophic phenotype could be reversed by various treatments that reduced the activity of the InsP 3 /Ca 2ϩ signaling pathway such as the expression of normal dystrophin (23, 81) , knockdown of the type 1 InsP 3 R, or its inhibition by 2-aminoethoxydiphenyl borate (259) . Inhibition of the InsP 3 R by over expressing Bcl-2 was also able to prevent apoptosis in dystrophic myotubes (28) . An increase in the activity of InsP 3 /Ca 2ϩ signaling also contributes to the muscular dystrophy that occurs in dilated cardiomyopathy (247) .
C. Cardiac Cells
The heart, which pumps blood around the body, is driven by the sinoatrial (SA) node pacemaker system. The pacemaker cells in the SA node generate the repetitive action potentials that travel through gap junctions to excite both the ventricular and atrial cells. The functions of these three cardiac cells that drive each heartbeat are modulated by the InsP 3 /Ca 2ϩ signaling pathway (387).
D. SA Node Pacemaker Cells
The cardiac pacemaker cells in the SA node are responsible for driving the rhythmical contraction of the heart. The specialized pacemaker cells in the SA have a sophisticated oscillatory mechanism based on both a membrane and a cytosolic Ca 2ϩ oscillator that generates the repetitive action potentials. The main component of the membrane oscillator is the HCN4 Na ϩ channel that is activated by hyperpolarization and then slowly decays to drive the slow pacemaker depolarization. The cytosolic Ca 2ϩ oscillator consists of both RYRs and InsP 3 Rs that interact with each other to release the pulse of Ca 2ϩ that then contributes to this pacemaker depolarization by enhancing the activity of Na ϩ /Ca 2ϩ exchanger (NCX) resulting in a I Na/Ca current. This periodic release of Ca 2ϩ from the SR depends on the activity of the SERCA pumps that refills the store, and this slow accumulation of Ca 2ϩ within the SR lumen acts to sensitize the RYRs to initiate periodic Ca 2ϩ sparks (389) . These sparks begin to develop toward the end of the pacemaker depolarization when they trigger a sudden release of Ca 2ϩ immediately preceding and contributing to the onset of the action potential. These bursts of Ca 2ϩ occur close to the cell surface where there is close apposition between the sarcoplasmic reticulum (SR) and the sarcolemma. The appearance of these sparks is facilitated by the InsP 3 /Ca 2ϩ signaling pathway that contributes to the activation of the RYRs responsible for the pacemaker depolarization. Activation of InsP 3 by either endothelin or ␣1-adrenergic receptors enhances both the frequency and amplitude of the Ca 2ϩ sparks that are driving the cardiac pacemaker potential (174) . The primary function of InsP 3 is to stimulate the InsP 3 R2 to release Ca 2ϩ that then acts to sensitize the RYRs to increase the frequency and amplitude of the Ca 2ϩ sparks (173, 182) .
E. Atrial Cardiac Cells
Contraction of the atrial chambers of the heart is driven by the striated atrial cells. Unlike the ventricular cells, the atria do not have t-tubules and the SR is closely applied to the sarcolemma through junctional zones that contain the RYR2 channels. The atrial cell Ca 2ϩ signal initiates at these junctional zones. The remainder of the SR sheet, which also contains RYRs, extends into the cell perpendicularly. The initial signal generated at the junctional zone is amplified and spreads into the cell by these nonjunctional RYRs. The atrial InsP 3 R2 receptors have two locations: the junctional zones and the nucleus (192, 214) . Those InsP 3 R2s that are located together with the RYRs in the junctional zone have a significant modulatory role in that they respond to endothelin-1 to induce a positive inotropic response.
In response to the atrial action potential, the L-type Ca 2ϩ channels in the sarcolemma facing the junctional zone generate a small pulse of Ca 2ϩ that activates the RYRs to create a Ca 2ϩ spark immediately below the sarcolemma. However, this small spark usually fails to ignite the RYRs on the rest of the SR and thus accounts for why atrial contractions are often rather weak. Much stronger contractions occur when atrial cells are stimulated by either a ␤-adrenergic agonist or by endothelin. There are two ways whereby these agonists induce a large positive inotropic response. First, they enhance the amplitude of the initial spark at the junctional zone so that it can breach the mitochondrial firewall to gain access to the nonjunctional RYR2s thereby generating a larger global Ca 2ϩ signal that drives stronger contractions. Second, these hormones can increase the sensitivity of the RYR2s that also enables the initial spark to create a Ca 2ϩ wave that penetrates the cell. The location of the InsP 3 receptors at the atrial cell junctional zone in immediate juxtaposition to the RYR2 thus enables them to play an important modulatory role in atrial cell excitation-contraction (E-C) coupling. The endothelin-1 acts on InsP 3 receptors in the junctional zone to augment the Ca 2ϩ spark sufficiently so that it spreads throughout the cell by recruiting the RYR2s on the nonjunctional SR to increase the force of contraction (192, 228) .
F. Atrial Arrhythmias
The most common cardiac arrhythmias are the atrial arrhythmias, which are caused by an increase in the InsP 3 / Ca 2ϩ signaling pathway. Endothelin acts to increase the formation of InsP 3 that results in the excessive Ca 2ϩ signaling responsible for the development of these atrial arrhythmias (159, 210, 227, 426) that can result in sudden heart death. In patients with chronic atrial fibrillation, there is an upregulation in the expression of the InsP 3 Rs (412). These arrhythmias also arise following deletion of the GTPaseactivating protein RGS4 that inhibits the G q/11 responsible for activating the PLC␤ that generates InsP 3 (278, 377) . A role for InsP 3 is supported by the observation that application of 2-aminoethoxydiphenyl, which had no effect on Ca 2ϩ signaling under control conditions, specifically suppressed atrial arrhythmias (227, 409) . Arrhythmias are also abolished in mice lacking InsP 3 R2 receptors (210) . Endothelin can also induce arrhythmias in ventricular cardiac myocytes that also are driven by InsP 3 (306) .
G. Ventricular Cardiac Cells
In ventricular cells, E-C coupling depends on the entry of Ca 2ϩ across the sarcolemma where it then activates the release of Ca 2ϩ by RYRs located on the sarcoplasmic reticulum (SR). This Ca 2ϩ -induced Ca 2ϩ release process is facilitated by a unique structural relationship between the sarcolemma and SR. The sarcolemma has regular tubular invaginations (t-tubules) that extend deep into the cell. At regular intervals along the length of the t-tubule there are junctional zones, which are specialized regions where the SR contacts the t-tubule. Each ventricular cell has ϳ10,000 junctional zones each of which has about 10 Ca V 1.2 L-type channels that face ϳ100 RYRs in the associated SR region. The L-type channels in the t-tubule region generate the trigger Ca 2ϩ that then stimulates the juxtaposed RYRs in the SR that face the t-tubule. Each of these events is induced by the action potential that sweeps along the sarcolemma to initiate ventricular cell E-C coupling.
This ventricular Ca 2ϩ signaling system can readily adapt to changes in cardiac function. Both positive and negative inotropy can be induced by various hormones acting in a reversible manner over short periods of time. In response to persistent modulatory signals, the ventricular cells can undergo phenotypic remodeling that induces an enlargement (hypertrophy) of the heart. This onset of hypertrophy can have pathological consequences if it progresses to CHF. Hypertrophy can thus be either physiological or pathological. In the former case, the hypertrophy is a normal compensatory response to an increase in work load and is reversible in that the heart reverts back to its previous shape once the work load is reduced. The irreversible CHF that results in sudden heart death develops when the pressure overload persists and there is a phenotypic change in the remodelling process that switches it from being a compensatory mechanism to a more pathological process.
H. Congestive Heart Failure
The dysfunctional cardiac remodeling that results in CHF is a major cause of human morbidity and mortality. A persistent increase in cardiac work load is one of the main causes that initiates the onset of CHF. One of the major causes of CHF is hypertension, which is associated with an increase in hormones such as endothelin-1, angiotensin II, and catecholamines. These hormones have a profound effect on the Ca 2ϩ dynamics of ventricular cells through their activation of phosphoinositide hydrolysis to increase the InsP 3 /Ca 2ϩ signaling pathway (192, 388) . In ventricular cells, the InsP 3 R2s are located on the nuclear membrane. The opening of these release channels depends on the presence of both InsP 3 and Ca 2ϩ (FIGURE 7). Even though endothelin-1 can enhance the level of InsP 3 in cardiac cells, it is not able to release Ca 2ϩ when acting by itself. However, during each cardiac Ca 2ϩ transient that drives contraction, there is a cytosolic pulse of Ca 2ϩ that can provide the costimulatory Ca 2ϩ signal necessary to activate the InsP 3 R2s that then creates a local Ca 2ϩ signal in the nucleus during the course of each contraction. This InsP 3 -dependent nuclear Ca 2ϩ signal is modulated by NCS-1, which is one of the regulators of the InsP 3 Rs (FIGURE 4) (266) . The InsP 3 R2s function as coincident detectors in that they integrate the InsP 3 signal generated by the endothelin-1 receptors and the contractile Ca 2ϩ signal to generate the nuclear Ca 2ϩ signal that activates the transcriptional events responsible for the onset of hypertrophy (148, 154, 214, 218, 267, 406, 427) . One of the genes that is activated is ITPR2 that codes for the InsP 3 R2 that is responsible for the nuclear Ca 2ϩ signal that drives hypertrophy (324) .
The persistent nuclear Ca 2ϩ pulses driven by the InsP 3 /Ca 2ϩ signaling pathway induces a process of dedifferentiation characterized by the activation of a program of fetal cardiac gene transcription. Cardiac function is markedly altered as a result of this remodeling, because there is a reduction in the amplitude of the Ca 2ϩ signal and the weaker cardiac contractions result in the failing heart. A particularly important change is the downregulation of the SERCA2a pump resulting from a decrease in its expression. In addition, this inhibition of SERCA2a is exacerbated by the inactivation of the adrenergic modulatory mechanism resulting in an increase in the activity of the Na ϩ /Ca 2ϩ exchanger that reduces the uptake of external Ca 2ϩ that further reduces the ability of the SERCA pump to load the SR with Ca 2ϩ . This decline in the ability of the SERCA pump to load the store with Ca 2ϩ results in larger diastolic Ca 2ϩ concentrations and a significant decline in the systolic Ca 2ϩ transient. This severe downregulation of Ca 2ϩ signaling brought about by the InsP 3 nuclear Ca 2ϩ signals is a characteristic feature of CHF.
I. Kawasaki Disease
Kawasaki disease is caused by vasculitis, and this inflammation of the blood vessels has an effect on many organs such as the heart, lymph nodes, skin, and mucous membranes inside the mouth, nose, and throat. It is characterized by high temperature that can last for 5 days. A significant aspect of the disease is acquired heart disease in children where it damages the coronary arteries resulting in inflammation of the heart, dysrhythmias, and aneurysms. The cause of this disease is still not clear, but there are indications that InsP 3 /Ca 2ϩ signaling may function to activate the T cells that contribute to the inflammatory response. Kawasaki disease has been linked to a mutation in the ITPKC gene that encodes the InsP 3 3-kinase that phosphorylates and inactivates the Ca 2ϩ -mobilizing activity of InsP 3 (FIGURE 2) (200, 277, 416) .
J. Smooth Muscle
Smooth muscle contraction and hypertension
Contraction of the smooth muscle cells (SMCs), which surround the vascular blood vessels, is driven by oscillatory Ca 2ϩ signals that are driven by the InsP 3 /Ca 2ϩ signaling pathway that is activated by transmitters such as ACh, 5-hydroxytryptamine (5-HT), and norepinephrine (NE) and hormones such as endothelin-1 (ET-1) (38) . The release of stored Ca 2ϩ , which drives these oscillations to maintain the vascular tone, is driven by both InsP 3 R and RYR channels. Variations in transmitter concentration are translated into changes in the frequency of the Ca 2ϩ oscillations and is another example of the frequency-modulated mechanism for regulating cellular function as described earlier (36, 47) .
An increase in the activity of the InsP 3 /Ca 2ϩ signaling pathway may contribute to the increased myogenic tone that results in the hypertension that induces cardiac disease (4). For example, in human pulmonary arterial SMCs, the enhanced expression of the Ca 2ϩ -sensing receptor (CaSR) acts to increase the activity of the InsP 3 /Ca 2ϩ signaling pathway (410) . In hypertensive rats, expression of the InsP 3 Rs is markedly elevated (1) . Increased entry of Ca 2ϩ through L-type channels acts through the calcineurin/NFAT transcriptional pathway to increase the expression of the InsP 3 Rs that contributes to hypertension through increased vascular smooth muscle (VSM) contractility. Such an action is consistent with the observation that there is increase in the expression of InsP 3 Rs in spontaneously hypertensive rats (SHRs) (32). Blood vessels are lined with endothelial cells that play an important role in regulating smooth muscle tone. Various stimuli act on these endothelial cells to stimulate InsP 3 /Ca 2ϩ signaling that then generates various vasoactive agents such as nitric oxide (NO), prostacyclin, and endothelium-derived hyperpolarizing factor, which act to control smooth muscle contractility. The increased blood pressure that occurs during hypertension results in a marked decline in the activity of InsP 3 /Ca 2ϩ signaling, and this interferes with the ability of the endothelial cells to reduce smooth muscle contraction (400).
Smooth muscle cell proliferation and asthma
Proliferation of smooth muscle cells is an example of how a differentiated cell can switch back into the cell cycle to return to cell division. This return to proliferation by SMCs is particularly significant for wound healing. However, such switching back into a proliferative state has a number of pathophysiological consequences in that it causes asthma, hypertension, and pulmonary vasoconstriction. In the case of pulmonary artery smooth muscle cells, proliferation is activated by a mechanism remarkably similar to that found in T cells (see above). An increase in InsP 3 releases Ca 2ϩ from the ER, and this then induces prolonged Ca 2ϩ signaling through the activation of the STIM1/Orai1 entry pathway (351, 428) .
Asthma and chronic obstructive pulmonary disease (COPD) are the two main respiratory diseases. The increase in SMC proliferation described above contributes to asthma because it results in a thickening of the bronchial wall. In addition, asthma is also caused by other alterations in the airways such as inflammation, bronchial hyperresponsiveness, and obstruction of the airways by excessive contraction of the SMCs. The excessive contraction of the airway SMCs, which is driven by the InsP 3 /Ca 2ϩ pathway, is one of the main causes of asthma (145) . In COPD, there is an overexpression of muscarinic M3 receptors that is responsible for the enhanced InsP 3 /Ca 2ϩ signaling pathway that drives the excessive contraction (294) . One of the most successful bronchodilators used to control COPD is tiotropium that acts by inhibiting the M3 receptors to reduce the elevated InsP 3 /Ca 2ϩ signaling to reduce SMC contraction and sputum production in airway mucous glands (294) . The extensive lung tissue damage that occurs during COPD is caused by the infiltration of neutrophils. This damage can be prevented by the secretory leukoprotease inhibitor (SLPI) that acts by reducing the activity of the InsP 3 /Ca 2ϩ signaling pathway that is responsible for neutrophil functions such as chemotaxis and the release of proteolytic enzymes (312).
VII. CHONDROCYTES
The maintenance of articular cartilage is carried out by the chondrocytes that regulate both the formation and the degradation of the matrix, which is composed of aggregan and collagen type II. The latter provides the tensile support, whereas the negatively charged proteoglycan aggrecan is responsible for the compressive resistance of cartilage in that it attracts water molecules to create its shock absorbing property (231) . The chondrocytes, which are embedded within cartilage, are responsible for synthesizing and assembling these extracellular matrix (ECM) components. Alterations in this synthetic role of the chondrocytes lead to changes in the properties of cartilage that are responsible for osteoarthritis.
A. Osteoarthritis
Osteoarthritis (OA) is a debilitating disease that is caused by degenerative changes in the cartilage that results in intense pain in the load-bearing joints such as the knees and hips. Chronic inflammation, which is a major contributory factor for OA, generates the cytokines and proteases that induce the chondrocytes to alter the synthesis of the type II collagen and proteoglycans. In addition, there is an increased release of matrix proteinases (MMPs) (e.g., MMP-1 and MMP-13) resulting in a dramatic alteration in cartilage composition (231) . The normal collagen II is replaced with collagen I, and there is a marked decline in the expression of aggrecan.
These pathological changes that give rise to OA depend on an alteration in the secretory activity of the chondrocytes that is driven by proinflammatory cytokines (TNF-␣ and IL-1␤). One of the causes for this alteration on chondrocyte activity is an increase in Ca 2ϩ signaling that occurs during OA (271, 304, 419) . For example, IL-1␤ acts on chondrocytes to increase the activity of the InsP 3 /Ca 2ϩ signaling pathway (304) . During OA, calcium phosphate crystals appear in the cartilage and contribute to cartilage destruction by activating Ca 2ϩ signals in the chondrocytes (271) .
The TNF-␣ may also act to enhance Ca 2ϩ signaling because it is known to increase the expression of the InsP 3 R1 (289). The importance of the InsP 3 /Ca 2ϩ signaling pathway in OA is highlighted by the observation that there is an increase in the expression of PLC␥2 and in some of the genes that regulate this enzyme (56) . There also is an increase in the expression of PLC␥1 in chondrocytes from patients with OA (410) . Reducing the activity of PLC␥1 by U73122 or by siRNA was able to restore the expression of collagen II and reduce the release of MMP-13 (419), thus emphasizing how an abnormal InsP 3 /Ca 2ϩ signaling pathway contributes to the pathological progression of osteoarthritis.
Korea. The KBD symptoms, which arise from cartilage damage, are joint pain, enlarged interphalangeal joints, and reduced movement in many joints of the body (330) . The causes of the disease are still not clear, but there does seem to be a link to various dietary components such as mycotoxins, fulvic acid, and deficiencies in selenium and iodine. Recently, a genome-wide association study has revealed that the ITPR2 gene that encodes the InsP 3 R2 channel is a susceptibility gene for KBD (423) . Chondrocyte necrosis and cell death is driven by mitochondrial-induced apoptosis (216, 393) . It is likely that this increase in apoptosis may be driven by an increase in the activity of the InsP 3 R2, which is known to release Ca 2ϩ from the ER to trigger apoptosis through the mitochondria (59, 363) .
VIII. EXOCRINE GLANDS
A. Pancreatic Acinar Cells
Both fluid and proteins are secreted by pancreatic acinar cells. The proteins are the digestive enzymes that are stored in the zymogen granules located in the apical part of the cell. Secretagogues such as cholecystokinin (CCK) and ACh induce the Ca 2ϩ signals that have spatial and temporal characteristics designed to maximize protein and fluid secretion (296) . ACh acts on muscarinic receptors to induce the InsP 3 /Ca 2ϩ signaling pathway. In addition to being located on the ER, the InsP 3 Rs are also found on the zymogen granules (295) . Neighboring RYRs act to amplify the Ca 2ϩ signal that generates a Ca 2ϩ wave that can extend into the basal region. The CCK uses a different signaling pathway in that it generates cyclic ADP ribose (cADPR) and nicotinic acid-adenine dinucleotide phosphate (NAADP) that release Ca 2ϩ from the acidic organelles and the ER.
As occurs in many other exocrine cells, the Ca 2ϩ signal is normally localized in the apical region where it appears as an oscillation that controls both fluid secretion and the release of zymogen granules. With regard to fluid secretion, the Ca 2ϩ stimulates apical Ca 2ϩ -sensitive Cl Ϫ channels (CaCCs), and the resulting entry of Cl Ϫ into the lumen provides the driving forces for the entry of both Na ϩ and water (288) .
The Ca 2ϩ signals located in the apical region are usually prevented from spreading into the rest of the cell by a mitochondrial firewall (376) . However, when stimuli are increased, there is a much larger apical Ca 2ϩ signal that breaches the mitochondrial firewall and spreads out towards the basal region in the form of a propagating Ca 2ϩ wave.
B. Pancreatitis
Pancreatitis has two forms. Acute pancreatitis appears suddenly and lasts for a few days. On the other hand, the chronic form can continue for many years. Chronic alcohol abuse is a major causes of pancreatitis. An increase in alcohol reduces the role of alcohol dehydrogenase (ADH) that functions normally to bring about the oxidative metabolism of ethanol. As a consequence, the nonoxidative metabolism of ethanol to fatty acid ethyl esters (FAEEs) is increased, which appears to be responsible for various alcoholic diseases such as pancreatitis (133) . In pancreatitis, one of the actions of FAEEs is to stimulate the type 2 and type 3 InsP 3 Rs that are found on the ER and zymogen granules. This leads to the pathogenic activation of the trypsin located in the apical zymogen granules (134) . Such activation of the digestive enzymes within the cell triggers a process of autodigestion leading to necrosis that is a feature of pancreatitis. In a mouse model, pancreatitis was prevented by deleting the InsP 3 R2 channels (279) . Caffeine can reduce the symptoms of acute pancreatitis by inhibiting the InsP 3 / Ca 2ϩ signaling pathway (164) . All this evidence supports the notion that an alteration in InsP 3 /Ca 2ϩ signaling plays a key role in the development of pancreatitis.
C. Salivary Gland
The function of salivary glands is to secrete saliva that facilitates the ingestion of food, and it also acts to moisten the oral cavity between meals. It is the small labial, buccal, and palatal glands that continuously secrete saliva to moisten the mouth. During feeding, much more saliva is required, and this is produced by the large submandibular, parotid, and sublingual salivary glands. Secretion by these glands is triggered by mechanical, thermal, or chemical stimuli. The main stimulus released from the parasympathetic neurons is ACh that binds to muscarinic (M3) receptors to activate the InsP 3 /Ca 2ϩ signaling system (9, 10, 244) . In the InsP 3 R2 and InsP 3 R3 double knockout mice, there is marked decline in salivary gland secretion (124). The resulting Ca 2ϩ signal depends both on Ca 2ϩ release from internal stores that is maintained by Ca 2ϩ entry through store-operated channels (SOCs). The increase in Ca 2ϩ stimulates the CaCCs that enables Cl Ϫ to enter the lumen where it provides the driving force for the entry of both Na ϩ and water. The elevated Ca 2ϩ also acts to open the BK channel that hyperpolarizes the basolateral membrane to create the electrochemical gradient that drives the movement of Cl Ϫ into the lumen.
D. Sjögren's Syndrome
Sjögren's syndrome (SS) is an autoimmune exocrinopathy that is characterized by a decline in fluid secretion by the salivary glands. A recent study has revealed that this secretory defect in the salivary glands of SS patients results from a decline in the expression of the InsP 3 Rs that function to release the Ca 2ϩ that activates fluid secretion (372) . This observation is consistent with the observation that patients with SS express anti-InsP 3 R antibodies (254) .
E. Sweat Glands
The tubular epithelial sweat glands located on the surface of the body consist of a distal secretory coil followed by a reabsorptive region. The secretory coil cells secrete an isotonic NaCl solution that then passes through the straighter reabsorptive region where most of the Na ϩ and Cl Ϫ is reabsorbed, and this results in the hypotonic sweat that is then transferred through pores onto the skin surface. Both parasympathetic and sympathetic neurons function to regulate the secretion of sweat. The norepinephrine (NE) released from the sympathetic neurons stimulates the cAMP signaling pathway to activate the cystic fibrosis transmembrane conductance regulator (CFTR) channel that transfers Cl Ϫ into the lumen of the sweat gland. In addition, the InsP 3 /Ca 2ϩ signaling pathway, which is activated by ACh released from the parasympathetic neurons, functions by activating CaCCs to create a flux of Cl Ϫ into the lumen. This Cl Ϫ transfer drives a parallel flux of Na ϩ which thus creates the accumulation of NaCl to provide the osmotic gradient for the flow of water.
F. Anhidrosis
In anhidrosis, which is also known as hypohidrosis, there is a marked decline in the formation of sweat that results in hyperthermia or heat stroke and can lead to death. The importance of the InsP 3 /Ca 2ϩ signaling pathway in sweat secretion, as described above, has emerged from the study of a missense ITPR2 gene mutation that encodes InsP 3 R2, which has been linked to anhidrosis in five members of a consanguineous family (191) .
G. Lung Submucosal Glands
The serous fluid-secreting cells in the submucosal glands of the lung function to secrete the fluid that contributes to the formation of the mucous that protects the lung airway epithelium against viruses, pathogens, and foreign particles. Various stimuli such as ACh, ATP, histamine, and substance P, which act through the InsP 3 /Ca 2ϩ signaling pathway, regulate the rate of fluid secretion (206) . The InsP 3 formed by these stimuli activates the type 1 InsP 3 R1 embedded in the ER positioned close to the apical membrane, to release Ca 2ϩ that then acts to open the CaCC.
IX. ENDOCRINE GLANDS
A. Pancreatic ␤-Cell Insulin Secretion
Elevation of glucose in the plasma stimulates insulin release from pancreatic ␤-cells by regulating both the biosynthesis and release of insulin. The way insulin is secreted is of interest clinically, because the development of diabetes results from the onset of insulin resistance caused by a decline in the secretion of insulin.
In addition to glucose, the activity of ␤-cells is also sensitive to other factors such as ACh, which is released by the ␣-cells, that acts in a paracrine manner to sensitize the ␤-cells to respond to glucose (315) . When considering the control of insulin secretion, therefore, it is necessary to understand both the primary action of glucose and how ACh acts through the InsP 3 /Ca 2ϩ pathway to modulate the activity of glucose (FIGURE 1). Elevated levels of plasma glucose induce a slow Ca 2ϩ oscillation (4 -6 min periodicity) that drives the secretion of insulin. Faster Ca 2ϩ spikes (10-to 20-s periodicity) occur during the crest of the slow Ca 2ϩ spikes.
The glucose transporter 2 (GLUT2) enables glucose to enter the ␤-cell where it is immediately phosphorylated by hexokinase IV to form glucose-6-phosphate (G-6-P). The G-6-P is then metabolized to fructose 6-phosphate (F-6-P), which is transformed into fructose-2,6-P 2 (F-2,6-P 2 ) by phosphofructose kinase-2 (PFK2). The next step is for the F-2,6-P 2 to activate PFK1 that transforms F-6-P to fructose-1,6-P 2 (F-1,6-P 2 ). The latter enters the glycolytic and tricarboxylic acid (TCA) cycles resulting in an elevation in ATP. The latter acts by inhibiting the ATP-sensitive K ϩ (K ATP ) channel resulting in the membrane depolarization that then activates the L-type voltage-operated channels (VOCs) to generate localized Ca 2ϩ pulses to induce the release insulin.
This primary role of glucose in stimulating insulin secretions can be modulated by the activity of other stimuli as illustrated by the action of ACh and free fatty acids (FFAs). The ACh acts through the M3 muscarinic receptor that operates through the InsP 3 /Ca 2ϩ pathway (25) and is another example of the modulatory role of this signaling system (FIGURE 1) . Similarly, the FFAs activate the GPR40 receptor that increases the InsP 3 /Ca 2ϩ pathway, which acts to potentiate glucose-induced insulin secretion (232) . There is a complex relationship between the glucose-induced Ca 2ϩ signal and the contribution from the InsP 3 /Ca 2ϩ pathway, which appear to act synergistically to control the release of insulin (130, 352).
B. Diabetes and Gallstone Formation
Alterations in the activity of the modulatory role of the InsP 3 /Ca 2ϩ pathway in regulating insulin secretion may contribute to the onset of diabetes (25) . For example, genetic variations in the M3 receptor, which normally activates the InsP 3 /Ca 2ϩ pathway, have been linked to earlyonset type 2 diabetes in Pima Indians (143) . Second-generation antipsychotics, such as olanzapine and clozapine, can result in insulin resistance through their ability to inhibit M3 receptors (399) . In a transgenic mouse line, a mutation in the Itpr1 gene that encodes the InsP 3 R1 channel has been linked to glucose intolerance and susceptibility to diet-induced diabetes (415) . It is also significant that there are alterations in the InsP 3 /Ca 2ϩ pathway during aging, and these changes may contribute to the onset of diabetes (26) . Vascular smooth muscle cell growth and dysfunction is induced by transforming growth factor-␤ (TGF-␤) (424) . One of the actions of TGF-␤ is to reduce the activity of InsP 3 R1, which may contribute to the diabetic pathophysiology of aortic and preglomerular smooth muscle cells (284, 340) .
In diabetic patients, there was a decreased expression of InsP 3 R and the cholycystokinin receptor (CCK-R), which generates InsP 3 (422) . The resulting decline in the InsP 3 / Ca 2ϩ signaling pathway accounts for the decline in gallbladder emptying and gallstone formation, which is a comorbidity often associated with diabetes.
X. LIVER
The liver has important functions, many of which are regulated through the InsP 3 /Ca 2ϩ signaling pathway (7, 27, 127, 128) . It regulates glucose and energy metabolism, synthesizes urea and a large number of plasma proteins, and is also responsible for bile secretion. InsP 3 /Ca 2ϩ signaling plays a central role in controlling the process of gluconeogenesis (238, 394) . Oxidative substrates are constantly being transferred between the plasma and liver cells. For example, when the supply of glucose is plentiful, insulin controls the uptake of glucose that is converted by glycogen synthase to glycogen that is stored in the liver. When glucose levels decline, the hormone glucagon stimulates glycogenolysis that results in the hydrolysis of glycogen to release glucose that can reenter the plasma. This glycogen hydrolysis is mediated by the enzyme phosphorylase, which is activated by phosphorylase kinase, which is a Ca 2ϩ -sensitive enzyme. Hormones such as vasopressin and norepinephrine act through the InsP 3 /Ca 2ϩ signaling system to stimulate the phosphorylase kinase to increase glycogenolysis.
The InsP 3 /Ca 2ϩ signaling pathway also acts to regulate bile secretion (8, 307) . The bile that is formed by the liver is transferred and stored in the gallbladder where it has two main functions. It contributes to fat digestion and absorption by the intestine, and it also functions to remove waste products from the blood. Bile secretion begins in the distal hepatocytes that transfer bile salts and other organic solutes into the canalicular lumen. This initial fluid is then passed down the canaliculus where it is modified by the cholangiocytes that are particularly active in secreting bicarbonate (HCO 3 Ϫ ). -activated K ϩ channels on the basolateral membrane that act to maintain a hyperpolarized membrane potential that is necessary to drive the flux of Cl Ϫ into the lumen. The apical membrane is also sensitive to ATP that is either released upstream by the hepatocytes and thus acts in a paracrine manner or is released by the cholangiocytes to act in an autocrine manner. The ATP stimulates P2Y receptors that generate InsP 3 that increases the release of Ca 2ϩ that drives secretion as described above.
A. Liver Cholestasis
Since the InsP 3 /Ca 2ϩ signaling pathway contributes to the control of many liver cell functions, it is not surprising to find that alteration in InsP 3 function plays a pivotal role in a number of liver diseases (8, 27, 342) . One of the serious liver diseases is cholestasis, which is caused by an alteration in the function of bile secretion. A decline in the expression of the type 3 InsP 3 R (InsP 3 R3) contributes to a number of cholestatic disorders such as obstruction of the bile duct, biliary atresia, biliary cholangitis/cirrhosis, and sclerosing cholangitis (7, 8) . The decline in the InsP 3 R may depend on various factors such as the nuclear factor, erythroid 2-like 2 (NRF2) transcription factor that acts to inhibit the expression of the ITP3R gene (397) and an increase in microRNA 506 (miR-506) that acts by reducing the expression of the InsP 3 R3 in the cholangiocytes (13) . Alterations in the activity of the InsP 3 R3 have also been implicated in various metabolic diseases. In particular, an increase in the InsP 3 / Ca 2ϩ signaling pathway contributes to the dysregulation of metabolism that occurs during insulin resistance and obesity (27) .
XI. OSTEOCLAST
The balance between the activity of the osteoclasts (bone resorption) and osteoblasts (bone formation) is central to the process of bone remodeling. Osteoclasts, which are derived from haematopoietic stem cells, are large multinucleated motile bone resorptive cells (153) . Their primary function is to degrade bone, and they are responsible for normal skeletal function and for calcium homeostasis. The ratio of osteoblasts to osteoclasts determines the process of bone remodeling. The rate of bone resorption depends on the formation and activity of the osteoclasts. As the osteoclasts are formed, they attach and spread out over the bone surface to initiate the process of bone resorption. The formation of osteoclasts, which is known as osteoclastogenesis, is controlled by factors such as colony-stimulating factor-1 (CSF-1), tumor necrosis-related factor called receptor activator of nuclear factor B (NF-B) ligand (RANKL), and inflammatory cytokines such as interleukins and TNF. Of the various signaling pathways that are activated by these factors, the Ca 2ϩ signaling pathway is beginning to attract considerable attention (123, 165, 268, 367, 420) .
Activation of the RANK pathway, which is particularly important for generating Ca 2ϩ signals, stimulates costimulatory transducing system such as FcR␥ and DAP12 that then activate PLC␥ to induce the formation of InsP 3 (193, 345) . The RANK pathway can also increase InsP 3 by acting on Rac1 to generate ROS that then activate PLC␥1 (188) . The InsP 3 formed by these two pathways then acts on the InsP 3 R2s to release Ca 2ϩ that sets up a prolonged Ca 2ϩ oscillation that then stimulates entry of NFATc1 into the nucleus where it induces transcription of those genes that drive osteoclast development (268, 367) . The ability of osteoprotegerin to inhibit osteoclast differentiation depends on its ability to reduce this Ca 2ϩ signaling pathway (123). As described below, the onset of rheumatoid arthritis is driven by excessive activation of this Ca 2ϩ signaling pathway.
A. Rheumatoid Arthritis
Rheumatoid arthritis (RA) is a chronic inflammatory disease that results in synovial inflammation and joint destruction that can lead to severe morbidity and premature mortality (5, 357) . The pathogenesis of RA is driven by autoreactive B cells (302) . One of the major cytokines driving osteoclast inflammation in RA is TNF-␣ (241, 270). Periodonitis is a related disease that is also caused by inflammation driven by TNF-␣ (153) . One of the actions of TNF-␣ is to enhance InsP 3 R1 expression, which induces osteoclastogenesis by increasing the Ca 2ϩ oscillations that are driven by the RANK signaling pathway (408) .
XII. NEPHROLITHIASIS
Nephrolithiasis arises due to an increase in kidney calcification that results in the formation of kidney stones (17) . These stones, which consist mainly of calcium phosphate and calcium oxalate, can develop both in the lumen of the kidney tubules and in the surrounding tissue. In addition to obstructing the tubule lumen, these Ca 2ϩ crystals may also damage the kidney through inflammatory reactions driven by cytokines such as TNF-␣ (184). There are multiple causes of nephrolithiasis, which is a complex disease. Stone formation has been linked to mutations of a number of genes that function in Ca 2ϩ signaling. A number of these genes such as CaSR (77, 339) , ITPKC (177) FIGURE 2) . Mutations in the ITPKC gene will result in an increase in the InsP 3 /Ca 2ϩ signaling pathway that will enhance the transepithelial flux of Ca 2ϩ that contributes to the formation of kidney stones.
XIII. CONCLUSION
The InsP 3 /Ca 2ϩ signaling pathway functions to regulate many different cellular processes. The versatility and universality of this signaling pathway is based on two main operational modes. In many cells, it provides the primary Ca 2ϩ signal that plays a direct role in regulating processes as diverse as fertilization, cell proliferation, secretion, metabolism, and smooth muscle contraction. Its other mode of action is to modulate the activity of various excitable cells such as neurons, insulin-secreting beta cells, as well as cardiac and skeletal muscle. In these cells the primary Ca What is remarkable about the primary and modulatory actions of the InsP 3 /Ca 2ϩ pathway is how it has been implicated in a large number diseases including some of the major human diseases such as cardiac and Alzheimer's diseases. The formation of InsP 3 is inhibited by Li ϩ and the release of Ca 2ϩ by the InsP 3 Rs is inhibited by caffeine. These two drugs have now been shown to alleviate or reduce the symptoms of a number of diseases such as Alzheimer's disease, bipolar disorder, Huntington's disease, and acute pancreatitis. 
